Evolent health, inc. (EVH)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash Flows Used In Operating Activities
Net loss

-305,580

-123,827

-110,644

-88,775

-54,191

-50,441

-51,015

-60,683

-69,767

-81,170

-83,816

-76,116

-226,778

-209,852

-211,165

157,322

319,814

0

0

0

Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:
Change in fair value of contingent consideration and indemnification asset

-3,997

-3,000

-2,400

-4,104

-4,104

-1,304

-1,304

500

400

0

0

0

-

-

-

-

-

-

-

-

Loss from equity method investees

-9,465

-8,136

-5,658

-5,036

-4,736

-3,096

-2,084

-1,333

-1,755

-1,825

-1,904

-1,363

-841

-462

-14

-16,846

-28,165

0

0

0

Depreciation and amortization expenses

60,913

59,599

54,543

49,285

44,515

41,014

38,379

35,249

32,368

27,732

23,760

20,468

17,224

13,854

13,165

10,537

7,166

0

0

0

Goodwill impairment

-

-

-

-

-

-

-

-

-

-

-

-

160,600

160,600

160,600

160,600

0

0

0

0

Stock-based compensation expense

15,618

20,094

18,383

18,351

17,609

16,825

18,486

19,128

20,437

20,932

20,023

19,373

18,604

18,038

17,621

19,065

14,730

0

0

0

Deferred tax provision (benefit)

-23,124

-178

997

-406

44

-4,569

-7,162

-7,718

-7,271

-11,809

-9,675

-9,362

-10,755

-7,323

-7,173

22,472

23,460

0

0

0

Amortization of contract cost assets

5,723

4,935

4,310

3,383

2,703

1,900

1,166

570

0

0

0

0

-

-

-

-

-

-

-

-

Amortization of deferred financing costs

9,370

8,721

6,596

4,505

2,455

917

917

914

914

685

456

229

0

0

0

0

-

-

-

-

Accretion of bond premium (discount)

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

Other current operating cash inflows (outflows), net

264

-534

-1,030

-1,081

-448

-291

-144

-125

-490

-561

-931

-965

-916

-522

-424

-282

-172

0

0

0

Changes in assets and liabilities, net of acquisitions:
Accounts receivable, net and contract assets

-6,326

6,922

-6,674

-7,428

24,503

17,184

24,642

24,390

11,258

14,514

8,990

10,212

11,044

-6,488

8,365

-6,921

-11,756

0

0

0

Prepaid expenses and other current and noncurrent assets

-791

844

10,875

6,310

14,746

7,539

8,612

9,252

-2,729

14,981

10,951

11,253

9,968

800

1,458

1,380

2,036

0

0

0

Contract cost assets

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Contract cost assets

23,057

21,593

18,527

15,389

11,179

4,568

762

355

0

0

0

0

-

-

-

-

-

-

-

-

Accounts payable

-5,480

-2,846

8,965

5,060

7,598

1,423

-1,820

3,675

5,563

7,912

3,645

747

-6,371

-2,001

902

-132

2,764

0

0

0

Accrued liabilities

-21,852

-22,427

1,873

10,576

12,180

22,240

6,980

9,155

-2,781

-2,011

9,084

7,088

15,229

8,761

-2,213

-2,374

-3,788

0

0

0

Accrued compensation and employee benefits

9,246

-5,932

-331

-4,592

-14,571

-2,655

481

-1,449

-3,303

-391

-5,018

-2,444

6,678

4,442

9,097

-900

11,402

0

0

0

Deferred revenue

-756

-530

-3,747

-10,952

-1,819

-459

5,096

9,836

3,548

3,153

3,906

2,287

1,200

-13,682

-6,176

-14,504

-17,998

0

0

0

Reserve for claims and performance-based arrangements

33,555

14,104

4,955

4,689

8,964

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use operating assets

20,811

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

27,724

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Claims reserves

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Other long-term liabilities

-5,355

-2,714

-2,440

-1,254

3,210

1,027

3,577

-1,209

-1,782

-1,989

-4,739

-928

-153

175

149

106

58

0

0

0

Net cash and restricted cash used in operating activities

-42,645

-80,800

-41,889

-21,655

-20,651

10,352

-8,150

-17,898

-27,958

-55,498

-51,404

-49,471

-35,510

-20,316

-34,578

-39,272

-18,468

0

0

0

Cash Flows Used In Investing Activities
Cash paid for asset acquisitions or business combinations

8,575

127,264

124,565

124,565

130,241

11,552

12,129

15,370

3,694

72,254

71,301

71,060

82,560

14,000

14,500

11,500

0

0

0

0

Customer advance for regulatory capital requirements

46,400

46,400

45,400

5,400

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Principal repayment of implementation funding loan and regulatory and capital requirements

5,400

11,400

14,830

16,000

20,000

14,000

8,000

4,000

0

0

0

0

-

-

-

-

-

-

-

-

Amount received from escrow in asset acquisition

0

0

0

0

500

500

500

500

0

0

0

0

-

-

-

-

-

-

-

-

Investments in and advances to equity method investees

87,480

19,666

22,252

5,697

9,360

7,935

5,128

5,128

1,128

0

0

0

-

-

-

-

-

-

-

-

Purchases of investments

11,125

18,910

17,132

13,789

10,010

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities and sales of investments

-

-

-

-

-

-

-

-

44,210

49,490

27,489

19,979

9,379

0

0

0

-

-

-

-

Investments in and purchases of property and equipment

35,534

36,810

37,046

39,459

39,550

35,616

35,661

31,423

27,848

25,759

20,696

18,151

15,526

13,724

12,760

9,868

6,515

0

0

0

Purchases of restricted investments

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchase and maturities of restricted investments

495

106

106

107

-7,937

-7,438

-7,438

-4,239

3,805

9,344

9,344

6,148

4,950

0

0

-1,198

-

0

0

0

Net cash and restricted cash used in investing activities

-181,634

-237,902

-231,815

-173,168

-160,375

-53,165

-32,980

-29,572

-12,265

-57,867

-76,852

-78,380

-96,657

-77,642

-78,200

-57,339

-43,684

0

0

0

Cash Flows (Used In) from Financing Activities
Changes in working capital balances related to claims processing on behalf of partners

-104,268

90,716

-16,095

10,921

96,153

4,104

10,539

-17,967

-4,200

0

0

0

-

-

-

-

-

-

-

-

Amount received from escrow in asset acquisition

500

500

500

500

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs related to 2025 Notes

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock option exercises

1,092

2,338

8,185

10,591

11,929

10,868

5,214

5,001

4,082

3,817

4,705

1,776

1,259

1,304

228

177

152

0

0

0

Taxes withheld and paid for vesting of restricted stock units

2,609

2,465

2,542

2,616

1,236

1,272

1,196

1,405

1,272

1,179

1,222

1,032

365

0

0

0

-

-

-

-

Net cash and restricted cash (used in) from financing activities

-35,545

257,660

156,618

185,966

274,024

13,700

181,504

152,576

165,557

293,228

130,777

141,534

150,185

5,863

4,834

214,188

214,163

0

0

0

Effect of exchange rate on cash and cash equivalents and restricted cash

30

-52

-72

-51

-36

35

7

-4

0

0

0

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-259,794

-61,094

-117,158

-8,908

92,962

-29,078

140,381

105,102

125,334

179,863

2,521

13,683

18,018

-92,095

-107,944

117,577

152,011

0

0

0

Supplemental Disclosure of Non-cash Investing and Financing Activities
Non-cash contribution of common stock to Evolent Health LLC prior to the Offering Reorganization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accrued property and equipment purchases

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

90

-

0

0

0

Class A common stock issued in connection with business combinations

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Increase to goodwill from measurement period adjustments related to business combinations

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Decrease in accrued financing costs related to 2021 Notes

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Decrease in non-controlling interests as a result of the Exchange

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Decrease in non-controlling interests as a result of Class B Exchanges

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-